Protagonist Therapeutics (PTGX) IPO Opened Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Protagonist Therapeutics Announces Pricing of Initial Public Offering
August 10, 2016 10:48 PM EDTMILPITAS, Calif., Aug. 10, 2016 /PRNewswire/ --Â Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs, today announced the pricing of its initial public offering of 7,500,000 shares of common stock, at a price to the public of $12 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market on August 11, 2016, under the symbol "PTGX." In addition,... More



